Amedeo Smart

Free Medical Literature Service


 

Amedeo

Liver Diseases

  Free Subscription

Articles published in
Lancet
    November 2023
  1. VON KODOLITSCH Y, Kubisch C, Carrel T
    AATD as a genetic risk factor for aneurysmal disease - Authors' reply.
    Lancet. 2023;402:1626.
    >> Share

  2. KUEPPERS F
    AATD as a genetic risk factor for aneurysmal disease.
    Lancet. 2023;402:1625-1626.
    >> Share

    October 2023
  3. VOGEL A, Meyer T, Saborowski A
    IMbrave050: the first step towards adjuvant therapy in hepatocellular carcinoma.
    Lancet. 2023 Oct 23:S0140-6736(23)01962-1. doi: 10.1016/S0140-6736(23)01962.
    >> Share

  4. QIN S, Chen M, Cheng AL, Kaseb AO, et al
    Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
    Lancet. 2023 Oct 20:S0140-6736(23)01796-8. doi: 10.1016/S0140-6736(23)01796.
    >> Share

    September 2023
  5. PINATO DJ, D'Alessio A, Celsa C, Manfredi GF, et al
    The price and value of therapeutic synergy in liver cancer.
    Lancet. 2023;402:1108-1110.
    >> Share

  6. TAPPER EB, Serper M
    Screening for advanced liver disease in the general population.
    Lancet. 2023;402:941-943.
    >> Share

  7. SERRA-BURRIEL M, Juanola A, Serra-Burriel F, Thiele M, et al
    Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study.
    Lancet. 2023;402:988-996.
    >> Share

    August 2023
  8. YAQUB S, Bjork I, Sugulle M, Folseraas T, et al
    Biopsy helpful in diagnosing a liver mass in pregnancy: focal nodular hyperplasia.
    Lancet. 2023;402:e10.
    >> Share

    July 2023
  9. QIN S, Chan SL, Gu S, Bai Y, et al
    Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
    Lancet. 2023 Jul 24:S0140-6736(23)00961-3. doi: 10.1016/S0140-6736(23)00961.
    >> Share

    May 2023
  10. ADAMS PC, Jeffrey G, Ryan J
    Haemochromatosis.
    Lancet. 2023;401:1811-1821.
    >> Share

    April 2023
  11. MAHGOUB S, Newsome PN
    Bariatric-metabolic surgery versus lifestyle intervention in non-alcoholic steatohepatitis.
    Lancet. 2023 Apr 20:S0140-6736(23)00773-0. doi: 10.1016/S0140-6736(23)00773.
    >> Share

  12. VERRASTRO O, Panunzi S, Castagneto-Gissey L, De Gaetano A, et al
    Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial.
    Lancet. 2023 Apr 20:S0140-6736(23)00634-7. doi: 10.1016/S0140-6736(23)00634.
    >> Share

    February 2023
  13. ALLISON MED, Verne J, Bernal W, Clayton M, et al
    Deaths from alcohol-related liver disease in the UK: an escalating tragedy.
    Lancet. 2023;401:418-420.
    >> Share

    September 2022
  14. VOGEL A, Meyer T, Sapisochin G, Salem R, et al
    Hepatocellular carcinoma.
    Lancet. 2022 Sep 6. pii: S0140-6736(22)01200.
    >> Share

    January 2022
  15. COOKE GS, Nayagam S
    Liver disease: at the heart of public health challenges for Europe in the 21st century.
    Lancet. 2022;399:9-10.
    >> Share

  16. KLEINERT S, Horton R
    An urgent challenge for Europe: from tackling liver diseases to protecting liver health.
    Lancet. 2022;399:7-9.
    >> Share

    December 2021
  17. NHLANE R, Kreuels B, Mallewa J, Chetcuti K, et al
    Late presentation of hepatocellular carcinoma highlights the need for a public health programme to eliminate hepatitis B.
    Lancet. 2021;398:2288.
    >> Share

  18. WATTS G
    Tom Hemming Karlsen: hepatologist with a public health message.
    Lancet. 2021 Dec 1. pii: S0140-6736(21)02746.
    >> Share

  19. KARLSEN TH, Sheron N, Zelber-Sagi S, Carrieri P, et al
    The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality.
    Lancet. 2021 Dec 1. pii: S0140-6736(21)01701.
    >> Share

    October 2021
  20. GONZALES E, Hardikar W, Stormon M, Baker A, et al
    Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study.
    Lancet. 2021;398:1581-1592.
    >> Share

  21. KRIEGERMEIER A, Taylor S
    Apical sodium-dependent bile acid transporter inhibition in children with Alagille syndrome.
    Lancet. 2021;398:1544-1545.
    >> Share

    September 2021
  22. GINES P, Krag A, Abraldes JG, Sola E, et al
    Liver cirrhosis.
    Lancet. 2021 Sep 17. pii: S0140-6736(21)01374.
    >> Share

  23. GURNARI C, Colak C, Zawit M, Maciejewski JP, et al
    Chronic Budd-Chiari syndrome in paroxysmal nocturnal haemoglobinuria.
    Lancet. 2021;398:e14.
    >> Share

    August 2021
  24. TIAN M, Zhang Z, Yuan Y
    When a young hepatobiliary surgeon faces his own liver lesions diagnosis.
    Lancet. 2021;398:746.
    >> Share

    April 2021
  25. POWELL EE, Wong VW, Rinella M
    Non-alcoholic fatty liver disease.
    Lancet. 2021 Apr 21. pii: S0140-6736(20)32511.
    >> Share

    March 2021
  26. WILLIAMS R, Alessi C, Alexander G, Allison M, et al
    New dimensions for hospital services and early detection of disease: a Review from the Lancet Commission into liver disease in the UK.
    Lancet. 2021 Mar 10. pii: S0140-6736(20)32396.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016